Donald A Berry

Giovanni Parmigiani, Susan G Hilsenbeck, Judy E Garber, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).

Larry Norton, Donald A Berry, Edith A Perez, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characterization of BRCA1 and BRCA2 mutations in a large United States sample.

Leif E. Peterson, Giovanni Parmigiani, Christopher I Amos, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer.

Roman Rouzier, Lajos Pusztai, Kenneth R Hess, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The difficult and ubiquitous problems of multiplicities

Donald A Berry, Donald A. Berry, 2007, Pharmaceutical statistics.

Adaptive clinical trials: a partial remedy for the therapeutic misconception?

Roger J Lewis, Donald A Berry, D. Berry, 2012, JAMA.

Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE

Brian M Alexander, Mitchel S Berger, Timothy F Cloughesy, 2017, Clinical Cancer Research.

Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.

Nola Hylton, Carolyn Mies, Olufunmilayo I Olopade, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer.

Scott M Berry, Pat Whitworth, Donald A Berry, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Richard L Schilsky, Larry Norton, James N Ingle, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Modeling the impact of population screening on breast cancer mortality in the United States.

Marvin Zelen, Harry J de Koning, Eric J Feuer, 2011, Breast.

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.

Funda Meric-Bernstam, Kristine R Broglio, Denis Larsimont, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012

Oguzhan Alagoz, Harry J de Koning, Xuelin Huang, 2018, JAMA.

A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drug

Michael Krams, Scott M Berry, Parvin Fardipour, 2010, Clinical trials.

Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status.

Brian L Sprague, Amy Trentham-Dietz, Donald A Berry, 2014, Epidemiologic reviews.

Addressing overdiagnosis and overtreatment in cancer: a prescription for change.

Sudhir Srivastava, Brian Reid, David F Ransohoff, 2014, The Lancet. Oncology.

Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality.

Oguzhan Alagoz, Eveline A M Heijnsdijk, Harry J de Koning, 2014, Journal of the National Cancer Institute.

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

Anne M Wallace, Michael Hogarth, Lajos Pusztai, 2016, The New England journal of medicine.

Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial.

Burr Hall, Hugh Calkins, Scott M Berry, 2010, JAMA.

HER2 and response to paclitaxel in node-positive breast cancer.

Larry Norton, James N Ingle, Matthew J Ellis, 2007, The New England journal of medicine.

Clinical trials: is the Bayesian approach ready for prime time? Yes!

Donald A Berry, D. Berry, 2005, Stroke.

The decrease in breast-cancer incidence in 2003 in the United States.

Eric J Feuer, Kathleen A Cronin, Nadia Howlader, 2007, The New England journal of medicine.

Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2.

Lorenzo Trippa, Brian M Alexander, Giovanni Parmigiani, 2013, Neuro-oncology.

Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.

Barbara L. Smith, Robert Livingston, Richard L Schilsky, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.

Larry Norton, Donald A Berry, D. Berry, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group.

Lorenzo Trippa, Brian M Alexander, Paul S Mischel, 2015, Neuro-oncology.

A Parallel Phase I/II Clinical Trial Design for Combination Therapies

Xuelin Huang, Donald A Berry, D. Berry, 2007, Biometrics.

NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry.

Donald A Berry, D. Berry, A. Gown, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

Role of detection method in predicting breast cancer survival: analysis of randomized screening trials.

Yu Shen, Lurdes Y T Inoue, Lurdes Y. T. Inoue, 2005, Journal of the National Cancer Institute.

A new Bayesian approach incorporating covariate information for heterogeneity and its comparison with HLOD

Donald A Berry, D. Berry, Shili Lin, 2005, BMC Genetics.

Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation

Roger J Lewis, Ari M Lipsky, Donald A Berry, 2007, Clinical trials.

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer

Anne Wallace, Emanuel F Petricoin, Rita Nanda, 2015, Clinical Cancer Research.

Using short‐term response information to facilitate adaptive randomization for survival clinical trials

Jing Ning, Xuelin Huang, Donald A Berry, 2009, Statistics in medicine.